UK
Catrin Treharne
She/HerI am a Partner and Health Economics Lead in the Health Analytics team, with more than 13 years of experience in health economics and health technology assessment.
I have expertise in economic evaluation across a wide number of disease areas, with some of my recent work covering oncology, gastroenterology, nephrology, and mental health. My experience spans the product life cycle, from early economic models to global models suited for health technology assessment, as well as models developed for use in local payer negotiations.
My prior experience includes leadership roles in health economics teams at Mtech Access and Parexel.
I have a BSc in Mathematics from the University of Exeter and an MSc in Health Economics from City, University of London.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
